Autopsy report · NCT02255162

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Slow Accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 4 months before it started.
Ran for about 1 year 11 months before it stopped.
8 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Massachusetts General Hospital
Sponsor type: University, hospital or other
Conditions: Acute Myeloid Leukemia (AML); Acute Myelocytic Leukemia; Acute Myelogenous Leukemia; Acute Granulocytic Leukemia; Acute Non-Lymphocytic Leukemia
Interventions: Lenalidomide; HLA-mismatched stem-cell Microtransplantation; Cytarabine
Participants: 8
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.